FAB — Fusion Antibodies Balance Sheet
0.000.00%
Last trade - 00:00- £3.58m
- £3.14m
- £2.90m
Annual balance sheet for Fusion Antibodies, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1.98 | 1.54 | 2.69 | 2.05 | 0.195 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.08 | 0.628 | 0.781 | 1.02 | 0.695 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 3.31 | 2.8 | 4.71 | 4.28 | 1.69 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.59 | 1.47 | 1.12 | 0.633 | 0.375 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 6.24 | 6.04 | 5.83 | 4.92 | 2.06 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.796 | 0.989 | 0.996 | 1.21 | 0.879 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.889 | 1.23 | 1.08 | 1.23 | 0.939 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 5.35 | 4.81 | 4.75 | 3.68 | 1.12 |
| Total Liabilities & Shareholders' Equity | 6.24 | 6.04 | 5.83 | 4.92 | 2.06 |
| Total Common Shares Outstanding |